Get started
Author

Muhammad Alamgeer

Observed names: Alamgeer, Muhammad, M. Alamgeer
Observed institutions: Monash Medical Centre, Frankston Hospital, Hudson Institute of Medical Research, Monash Health, Olivia Newton-John Cancer Research Institute, Monash University, Monash Institute of Medical Research
ORCID: 0000-0002-6443-2350
Observed ORCID: 0000-0002-6443-2350
OpenAlex ID: A5022491020
Cancer stem cells in lung cancer: Evidence and controversies
2013 · Muhammad Alamgeer, Craig D. Peacock, et al. · Respirology · 143
PDF
The Evolution of Therapies in Non-Small Cell Lung Cancer
2015 · Vishal Boolell, Muhammad Alamgeer, et al. · Cancers · 127
PDF
Novel therapeutic targets in non-small cell lung cancer
2013 · Muhammad Alamgeer, Vinod Ganju, et al. · Current Opinion in Pharmacology · 80
Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors
2016 · Andrea Muscat, Dean Popovski, et al. · Clinical Cancer Research · 71
The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer
2013 · Muhammad Alamgeer, Vinod Ganju, et al. · Thorax · 69
PDF
Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer
2014 · Muhammad Alamgeer, Vinod Ganju, et al. · Breast Cancer Research · 55
PDF
Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy
2018 · Kieren D. Marini, David R. Croucher, et al. · Science Translational Medicine · 45
Frailty and long-term survival among patients in Australian intensive care units with metastatic cancer (FRAIL-CANCER study): a retrospective registry-based cohort study
2023 · Muhammad Alamgeer, Ryan Ruiyang Ling, et al. · The Lancet Healthy Longevity · 42
A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer
2017 · Muhammad Alamgeer, D. Neil Watkins, et al. · Investigational New Drugs · 40
Genomic Characterisation of Small Cell Lung Cancer Patient-Derived Xenografts Generated from Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Specimens
2014 · Tracy L. Leong, Kieren D. Marini, et al. · PLoS ONE · 38
PDF
Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer
2018 · Tracy L. Leong, Velimir Gayevskiy, et al. · Oncogene · 37
PDF
MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
2023 · Jasmine Chen, Aleks C. Guanizo, et al. · Journal of Experimental & Clinical Cancer Research · 33
PDF
Circulating Tumour DNA (ctDNA) as a Predictor of Clinical Outcome in Non-Small Cell Lung Cancer Undergoing Targeted Therapies: A Systematic Review and Meta-Analysis
2023 · Farzana Y. Zaman, Ashwin Subramaniam, et al. · Cancers · 23
PDF
Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma
2020 · Natasha K. Brockwell, Muhammad Alamgeer, et al. · Translational Lung Cancer Research · 22
PDF
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study
2024 · Luke S McLean, Annette M Lim, et al. · The Medical Journal of Australia · 21
PDF
Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer
2019 · Caroline Lum, Muhammad Alamgeer · Cancers · 20
PDF
FRailty in Australian patients admitted to Intensive care unit after eLective CANCER-related SURGery: a retrospective multicentre cohort study (FRAIL-CANCER-SURG study)
2024 · Ryan R. Ling, Ryo Ueno, et al. · British Journal of Anaesthesia · 17
Impact of Pretreatment Combined 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer
2015 · Sweet Ping Ng, Steven David, et al. · International Journal of Radiation Oncology*Biology*Physics · 17
Atherosclerotic Cardiovascular Events in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Retrospective Cohort Study
2023 · Sean Tan, Ella Spear, et al. · Heart Lung and Circulation · 9
PDF
Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy
2023 · Yang Wang, Jared Mathai, et al. · JTO Clinical and Research Reports · 6
PDF
A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).
2022 · Andrew Mark Haydon, Nikhil I. Khushalani, et al. · Journal of Clinical Oncology · 5
Treatment outcomes of standard (high dose) cisplatin and non‐standard chemotherapy for locally advanced head and neck cancer
2022 · Muhammad Alamgeer, Andrew Coleman, et al. · Cancer Reports · 3
PDF
P1.07-004 Updated Analysis of Phase II Study of HA-Irinotecan, a CD44-Targeting Formulation of Hyaluronic Acid and Irinotecan, in Small Cell Lung Cancer
2017 · Muhammad Alamgeer, Peter Briggs, et al. · Journal of Thoracic Oncology · 3
PDF
Oncology and intensive care doctors' perception of intensive care admission of cancer patients: A cross-sectional national survey
2024 · Swarup Padhi, Prajwol Shrestha, et al. · Australian Critical Care · 2
1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]
2021 · A.M. Haydon, M. Alamgeer, et al. · Annals of Oncology · 2
Works count: 45
Citation count: 934
H-index: 17
I10-index: 18
Year
Topic
Type